Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Chokri Ben Lamine: Laboratory Findings and Management of Severe Type 3 von Willebrand Disease
AI generated
Apr 2, 2026, 08:22

Chokri Ben Lamine: Laboratory Findings and Management of Severe Type 3 von Willebrand Disease

Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:

“Type 3 VWD equals near‑total absence of vWF, which is the most severe form.

Family – autosomal recessive; think consanguinity.

Phenotype

  • Mucocutaneous bleeding (epistaxis, gums, menorrhagia)
  • Deep bleeding, such as hemarthrosis and muscle bleeding, results in a clinical picture that mimics hemophilia A.

Labs

  • vWF:Ag and activity absent
  • Factor VIII very low – less than ten percent.
  • aPTT prolonged
  • PT normal

Pearl: DDAVP is ineffective because there is no endogenous von Willebrand factor available to release.

Life-threatening bleeding (ICH, GI, major trauma)

  • Immediate vWF-containing concentrate (Humate-P, Wilate) high dose
  • Target: normalize vWF activity and FVIII rapidly
  • Repeat dosing q8-12h based on levels/clinical response
  • Add FVIII if levels critically low or delayed response
  • ICU-level care plus local hemostatic measures

Non–life-threatening bleeding (epistaxis, menorrhagia, minor procedures)

  • vWF-containing concentrate (lower dose / shorter duration)
  • Tranexamic acid for mucosal bleeding
  • Local measures (pressure, topical TXA, nasal packing, etc.)

Complication: Alloantibodies to vWF lead poor response / anaphylaxis risk change symbols to words.”

Stay updated with Hemostasis Today.

bleeding disorders Chokri Ben Lamine Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Medicine Type 3 VWD VWF
NewsFeed